Subscribe to RSS
DOI: 10.1055/s-0040-1715606
Cochlear Implantation in Vestibular Schwannoma: A Systematic Literature Review
![](https://www.thieme-connect.de/media/jnlsb/202106/lookinside/thumbnails/10-1055-s-0040-1715606_200008-1.jpg)
Abstract
Objective Ipsilateral cochlear implantation (CI) in vestibular schwannoma (VS) has been an emerging trend over the last two decades. We conducted the first systematic review of hearing outcomes comparing neurofibromatosis 2 (NF2) and sporadic VS undergoing CI. A comparison of the two populations and predictor of outcome was assessed. This is an update to a previously presented study.
Data Sources Systemic data searches were performed in PubMed NCBI and Scopus by an academic librarian. No restrictions based on the year of publication were used.
Study Selection Studies were selected if patients had a diagnosis of NF2 and a CI placed in the affected side with reports of hearing outcome. Two independent reviewers screened each abstract and full-text article.
Data Extraction Studies were extracted at the patient level, and the assessment of quality and bias was evaluated according to the National Institutes of Health Quality Assessment Tool.
Main Outcome Measures Outcome predictors were determined by using the chi-square test and Student's t-test.
Results Overall, most CI recipients functioned in the high-to-intermediate performer category for both sporadic and NF2-related VS. Median AzBio (Arizona Biomedical Institute Sentence Test) was 72% (interquartile range [IQR]: 50) in NF2 patients and 70% (IQR: 7.25) in sporadic patients. Larger tumor size predicted a poorer final audiometric outcome.
Conclusions Categorization of hearing outcome into superior performance and inferior performance based on sentence recognition revealed a generally good hearing outcome regardless of treatment or patient population. Select patients with sporadic and NF2 VS may benefit from CI.
Keywords
vestibular schwannoma - acoustic neuroma - neurofibromatosis type 2 - cochlear implant - hearing conservation surgery - hearing rehabilitation - stereotactic radiosurgeryPublication History
Received: 11 January 2020
Accepted: 22 May 2020
Article published online:
08 June 2021
© 2021. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Evans DG, Huson SM, Donnai D. et al. A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet 1992; 29 (12) 841-846
- 2 Evans DGR, Moran A, King A, Saeed S, Gurusinghe N, Ramsden R. Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol 2005; 26 (01) 93-97
- 3 Martuza RL, Eldridge R. Neurofibromatosis 2 (bilateral acoustic neurofibromatosis). N Engl J Med 1988; 318 (11) 684-688
- 4 Mautner VF, Tatagiba M, Guthoff R, Samii M, Pulst SM. Neurofibromatosis 2 in the pediatric age group. Neurosurgery 1993; 33 (01) 92-96
- 5 Soulier G, van Leeuwen BM, Putter H. et al. Quality of life in 807 patients with vestibular schwannoma: comparing treatment modalities. Otolaryngol Head Neck Surg 2017; 157 (01) 92-98
- 6 Carlson ML, Habermann EB, Wagie AE. et al. The changing landscape of vestibular schwannoma management in the United States--a shift toward conservatism. Otolaryngol Head Neck Surg 2015; 153 (03) 440-446
- 7 Elliott A, Hebb ALO, Walling S, Morris DP, Bance M. Hearing preservation in vestibular schwannoma management. Am J Otolaryngol 2015; 36 (04) 526-534
- 8 Daniel RT, Tuleasca C, George M. et al. Preserving normal facial nerve function and improving hearing outcome in large vestibular schwannomas with a combined approach: planned subtotal resection followed by gamma knife radiosurgery. Acta Neurochir (Wien) 2017; 159 (07) 1197-1211
- 9 Lloyd SKW, King AT, Rutherford SA. et al. Hearing optimisation in neurofibromatosis type 2: A systematic review. Clin Otolaryngol 2017; 42 (06) 1329-1337
- 10 Edgerton BJ, House WF, Hitselberger W. Hearing by cochlear nucleus stimulation in humans. Ann Otol Rhinol Laryngol Suppl 1982; 91 (2 Pt 3): 117-124
- 11 Hitselberger WE, House WF, Edgerton BJ, Whitaker S. Cochlear nucleus implants. Otolaryngol Head Neck Surg 1984; 92 (01) 52-54
- 12 Hoffman RA, Kohan D, Cohen NL. Cochlear implants in the management of bilateral acoustic neuromas. Am J Otol 1992; 13 (06) 525-528
- 13 Neff BA, Wiet RM, Lasak JM. et al. Cochlear implantation in the neurofibromatosis type 2 patient: long-term follow-up. Laryngoscope 2007; 117 (06) 1069-1072
- 14 Peng KA, Lorenz MB, Otto SR, Brackmann DE, Wilkinson EP. Cochlear implantation and auditory brainstem implantation in neurofibromatosis type 2. Laryngoscope 2018; 128 (09) 2163-2169
- 15 Bartindale MR, Tadokoro KS, Kircher ML. Cochlear implantation in sporadic vestibular schwannoma: a systematic literature review. J Neurol Surg B Skull Base 2019; 80 (06) 632-639
- 16 Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42 (02) 377-381
- 17 Carlson ML, Breen JT, Driscoll CL. et al. Cochlear implantation in patients with neurofibromatosis type 2: variables affecting auditory performance. Otol Neurotol 2012; 33 (05) 853-862
- 18 National Institutes of Health. Quality Assessment Tool for Case Series Studies. https://www.nhlbi.nih.gov/health-pro/guidelines/in-develop/cardiovascular-risk-reduction/tools/case_series . Accessed August 28, 2019
- 19 Evans DG, Huson SM, Donnai D. et al. A clinical study of type 2 neurofibromatosis. Q J Med 1992; 84 (304) 603-618
- 20 Patel CM, Ferner R, Grunfeld EA. A qualitative study of the impact of living with neurofibromatosis type 2. Psychol Health Med 2011; 16 (01) 19-28
- 21 Neary WJ, Hillier VF, Flute T, Stephens D, Ramsden RT, Evans DGR. Use of a closed set questionnaire to measure primary and secondary effects of neurofibromatosis type 2. J Laryngol Otol 2010; 124 (07) 720-728
- 22 Mahboubi H, Maducdoc MM, Yau AY. et al. Vestibular schwannoma excision in sporadic versus neurofibromatosis type 2 populations. Otolaryngol Head Neck Surg 2015; 153 (05) 822-831
- 23 Otto SR, Brackmann DE, Hitselberger WE, Shannon RV, Kuchta J. Multichannel auditory brainstem implant: update on performance in 61 patients. J Neurosurg 2002; 96 (06) 1063-1071
- 24 Lenarz T, Moshrefi M, Matthies C. et al. Auditory brainstem implant: part I. Auditory performance and its evolution over time. Otol Neurotol 2001; 22 (06) 823-833
- 25 Nevison B, Laszig R, Sollmann W-P. et al. Results from a European clinical investigation of the Nucleus multichannel auditory brainstem implant. Ear Hear 2002; 23 (03) 170-183
- 26 Harris F, Tysome JR, Donnelly N. et al. Cochlear implants in the management of hearing loss in neurofibromatosis type 2. Cochlear Implants Int 2017; 18 (03) 171-179
- 27 North HJD, Mawman D, O'Driscoll M. et al. Outcomes of cochlear implantation in patients with neurofibromatosis type 2. Cochlear Implants Int 2016; 17 (04) 172-177
- 28 Lloyd SKW, Glynn FJ, Rutherford SA. et al. Ipsilateral cochlear implantation after cochlear nerve preserving vestibular schwannoma surgery in patients with neurofibromatosis type 2. Otol Neurotol 2014; 35 (01) 43-51
- 29 Reznitsky M, Cayé-Thomasen P. Systematic review of hearing preservation in observed vestibular schwannoma. J Neurol Surg B Skull Base 2019; 80 (02) 165-168
- 30 Martin TPC, Senthil L, Chavda SV, Walsh R, Irving RM. A protocol for the conservative management of vestibular schwannomas. Otol Neurotol 2009; 30 (03) 381-385
- 31 Mahboubi H, Sahyouni R, Moshtaghi O. et al. CyberKnife for treatment of vestibular schwannoma: a meta-analysis. Otolaryngol Head Neck Surg 2017; 157 (01) 7-15
- 32 Pisa J, Sulkers J, Butler JB, West M, Hochman JB. Stereotactic radiosurgery does not appear to impact cochlear implant performance in patients with neurofibromatosis type II. J Radiosurg SBRT 2017; 5 (01) 63-71
- 33 Costello MS, Golub JS, Barrord JV, Pater L, Pensak ML, Samy RN. Cochlear implantation after radiation therapy for acoustic neuroma. J Radiosurg SBRT 2016; 4 (01) 69-74
- 34 Adams RD. The neuropathology of radiosurgery. Stereotact Funct Neurosurg 1991; 57 (1-2): 82-86
- 35 Wackym PA, Runge-Samuelson CL, Nash JJ. et al. Gamma knife surgery of vestibular schwannomas: volumetric dosimetry correlations to hearing loss suggest stria vascularis devascularization as the mechanism of early hearing loss. Otol Neurotol 2010; 31 (09) 1480-1487
- 36 Buchman CA, Chen DA, Flannagan P, Wilberger JE, Maroon JC. The learning curve for acoustic tumor surgery. Laryngoscope 1996; 106 (11) 1406-1411
- 37 Mangham Jr CA. Retrosigmoid versus middle fossa surgery for small vestibular schwannomas. Laryngoscope 2004; 114 (08) 1455-1461
- 38 Wilkinson EP, Roberts DS, Cassis A, Schwartz MS. Hearing outcomes after middle fossa or retrosigmoid craniotomy for vestibular schwannoma tumors. J Neurol Surg B Skull Base 2016; 77 (04) 333-340
- 39 Linthicum Jr FH, Brackmann DE. Bilateral acoustic tumors. A diagnostic and surgical challenge. Arch Otolaryngol 1980; 106 (12) 729-733
- 40 Adunka OF, Gantz BJ, Dunn C, Gurgel RK, Buchman CA. Minimum reporting standards for adult cochlear implantation. Otolaryngol Head Neck Surg 2018; 159 (02) 215-219
- 41 Luxford WM. Ad Hoc Subcommittee of the Committee on Hearing and Equilibrium of the American Academy of Otolaryngology-Head and Neck Surgery. Minimum speech test battery for postlingually deafened adult cochlear implant patients. Otolaryngol Head Neck Surg 2001; 124 (02) 125-126
- 42 Sladen DP, Carlson ML, Dowling BP. et al. Cochlear implantation in adults with asymmetric hearing loss: speech recognition in quiet and in noise, and health related quality of life. Otol Neurotol 2018; 39 (05) 576-581
- 43 Carlson ML, Neff BA, Link MJ. et al. Magnetic resonance imaging with cochlear implant magnet in place: safety and imaging quality. Otol Neurotol 2015; 36 (06) 965-971
- 44 Edmonson HA, Carlson ML, Patton AC, Watson RE. MR imaging and cochlear implants with retained internal magnets: reducing artifacts near highly inhomogeneous magnetic fields. Radiographics 2018; 38 (01) 94-106
- 45 Lassaletta L, Polak M, Huesers J. et al. Usefulness of electrical auditory brainstem responses to assess the functionality of the cochlear nerve using an intracochlear test electrode. Otol Neurotol 2017; 38 (10) e413-e420
- 46 Cinar BC, Yarali M, Atay G, Bajin MD, Sennaroglu G, Sennaroglu L. The role of eABR with intracochlear test electrode in decision making between cochlear and brainstem implants: preliminary results. Eur Arch Otorhinolaryngol 2017; 274 (09) 3315-3326
- 47 Kasbekar AV, Tam YC, Carlyon RP. et al. Intraoperative monitoring of the cochlear nerve during neurofibromatosis type-2 vestibular schwannoma surgery and description of a “test intracochlear electrode”. J Neurol Surg Rep 2019; 80 (01) e1-e9
- 48 Tan H, Jia H, Li Y. et al. Impact of cochlear implantation on the management strategy of patients with neurofibromatosis type 2. Eur Arch Otorhinolaryngol 2018; 275 (11) 2667-2674
- 49 Dos Santos NetoPH, Zamponi JO, Hamerschmidt R, Wiemes GRM, Rassi MS, Borba LAB. Simultaneous cochlear implantation as a therapeutic option in vestibular schwannoma surgery: case report. Neurosurg Focus 2018; 44 (03) E9
- 50 DeHart AN, Broaddus WC, Coelho DH. Translabyrinthine vestibular schwannoma resection with simultaneous cochlear implantation. Cochlear Implants Int 2017; 18 (05) 278-284
- 51 Carlson ML, Neff BA, Sladen DP, Link MJ, Driscoll CL. Cochlear Implantation in Patients With Intracochlear and Intralabyrinthine Schwannomas. Otol Neurotol 2016; 37 (06) 647-653
- 52 Pimentel PS, Ramos DS, Muniz L, Leal M de C, Caldas Neto S da S. Cochlear implant in a patient with neurofibromatosis type 2 undergoing radiotherapy. Braz J Otorhinolaryngol 2016; 82 (02) 242-243
- 53 Ozdek A, Bayir O, Dönmez T. et al. Hearing restoration in NF2 patients and patients with vestibular schwannoma in the only hearing ear: report of two cases. Am J Otolaryngol 2014; 35 (04) 538-541
- 54 Lassaletta L, Aristegui M, Medina M. et al. Ipsilateral cochlear implantation in patients with sporadic vestibular schwannoma in the only or best hearing ear and in patients with NF2. Eur Arch Otorhinolaryngol 2016; 273 (01) 27-35
- 55 Pai I, Dhar V, Kelleher C. et al. Cochlear implantation in patients with vestibular schwannoma: a single United Kingdom center experience. Laryngoscope 2013; 123 (08) 2019-2023
- 56 Amoodi HA, Makki FM, Cavanagh J, Maessen H, Bance M. Cochlear implant rehabilitation for patients with vestibular schwannoma: report of two cases. Cochlear Implants Int 2012; 13 (02) 124-127
- 57 Monteiro TA, Goffi-Gomez MVS, Tsuji RK, Gomes MQT, Brito Neto RV, Bento RF. Neurofibromatosis 2: hearing restoration options. Braz J Otorhinolaryngol 2012; 78 (05) 128-134
- 58 Mukherjee P, Ramsden JD, Donnelly N. et al. Cochlear implants to treat deafness caused by vestibular schwannomas. Otol Neurotol 2013; 34 (07) 1291-1298
- 59 Cruz OLM, Vellutini EAS. Cochlear implant in type 2 neurofibromatosis: an option for better hearing rehabilitation. Braz J Otorhinolaryngol 2011; 77 (04) 538
- 60 Odat HA, Piccirillo E, Sequino G, Taibah A, Sanna M. Management strategy of vestibular schwannoma in neurofibromatosis type 2. Otol Neurotol 2011; 32 (07) 1163-1170
- 61 Roehm PC, Mallen-St ClairJ, Jethanamest D. et al. Auditory rehabilitation of patients with neurofibromatosis Type 2 by using cochlear implants. J Neurosurg 2011; 115 (04) 827-834
- 62 Trotter MI, Briggs RJS. Cochlear implantation in neurofibromatosis type 2 after radiation therapy. Otol Neurotol 2010; 31 (02) 216-219
- 63 Tran Ba HuyP, Kania R, Frachet B, Poncet C, Legac M-S. Auditory rehabilitation with cochlear implantation in patients with neurofibromatosis type 2. Acta Otolaryngol 2009; 129 (09) 971-975
- 64 Vincenti V, Pasanisi E, Guida M, Di Trapani G, Sanna M. Hearing rehabilitation in neurofibromatosis type 2 patients: cochlear versus auditory brainstem implantation. Audiol Neurootol 2008; 13 (04) 273-280
- 65 Lustig LR, Yeagle J, Driscoll CLW, Blevins N, Francis H, Niparko JK. Cochlear implantation in patients with neurofibromatosis type 2 and bilateral vestibular schwannoma. Otol Neurotol 2006; 27 (04) 512-518
- 66 Arístegui M, Denia A. Simultaneous cochlear implantation and translabyrinthine removal of vestibular schwannoma in an only hearing ear: report of two cases (neurofibromatosis type 2 and unilateral vestibular schwannoma). Otol Neurotol 2005; 26 (02) 205-210
- 67 Nölle C, Todt I, Basta D, Unterberg A, Mautner VF, Ernst A. Cochlear implantation after acoustic tumour resection in neurofibromatosis type 2: impact of intra- and postoperative neural response telemetry monitoring. ORL J Otorhinolaryngol Relat Spec 2003; 65 (04) 230-234
- 68 Graham J, Lynch C, Weber B, Stollwerck L, Wei J, Brookes G. The magnetless Clarion cochlear implant in a patient with neurofibromatosis 2. J Laryngol Otol 1999; 113 (05) 458-463
- 69 Temple RH, Axon PR, Ramsden RT, Keles N, Deger K, Yöcel E. Auditory rehabilitation in neurofibromatosis type 2: a case for cochlear implantation. J Laryngol Otol 1999; 113 (02) 161-163
- 70 Tono T, Ushisako Y, Morimitsu T. Cochlear implantation in an intralabyrinthine acoustic neuroma patient after resection of an intracanalicular tumour. J Laryngol Otol 1996; 110 (06) 570-573